IP Library Granted Patent US 8,465,933
Granted Patent B2
US 8,465,933 · App. 12/987,518 · Granted Jun 18, 2013

Method for screening human ABO blood group-binding lactobacilli

Inventors: Tadao Saito (Miyagi, JP); Yasushi Kawai (Miyagi, JP); Hideaki Uchida (Miyagi, JP); Katsunori Kimura (Kanagawa, JP); Kakuhei Isawa (Kanagawa, JP); Keisuke Furuichi (Kanagawa, JP)
Assignee: Meiji Co., Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,465,933
App. No.
12/987,518
Granted
Jun 18, 2013
Kind
B2
Abstract

Lactobacillus screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 lactobacillus strains, the above-mentioned screening methods and tests to judge their compatibility for the use of yogurt production were carried out, to at long last specifically discover bacillus strains compatible with blood groups A, B, and O.

Claims (38)

1. A method of screening for a human blood group A-compatible lactobacillus , comprising:

(a) providing a candidate lactobacillus;

(b) determining ability of the candidate lactobacillus to recognize a human blood group A antigen, a human blood group B antigen, and a human blood group H antigen, wherein the recognizing ability is determined by measuring response units (RU) of surface plasmon resonance spectrum, wherein the human blood group A antigen comprises [GalNAcα1-3(Fucα1-2)Gal-]; and

(c) selecting the candidate lactobacillus as a human blood group A-compatible lactobacillus if:

(i) blood group A antigen-recognizing ability is 2,000 RU or higher;

(ii) blood group B antigen-recognizing ability is 100 RU or lower;

(iii) blood group H antigen-recognizing ability is 100 RU or lower;

(iv) ratio of the blood group A antigen-recognizing ability to the blood group B antigen-recognizing ability is 70 or higher;

(v) ratio of the blood group A antigen-recognizing ability to the blood group H antigen-recognizing ability is 100 or higher;

(vi) A-HCM-recognizing ability is 100 RU or higher; and

(vii) O-HCM-recognizing ability is 100 RU or lower.

2. The method, according to claim 1 , wherein the human blood group B antigen comprises [Galα1-3 (Fucα1-2)Gal-].

3. The method, according to claim 1 , wherein the human blood group H antigen comprises [Fucα1-2Gal-].

4. A method of screening for a human blood group B-compatible lactobacillus , comprising:

(a) providing a candidate lactobacillus;

(b) determining ability of the candidate lactobacillus to recognize a human blood group A antigen, a human blood group B antigen, and a human blood group H antigen using surface plasmon resonance, wherein the recognizing ability is determined by measuring response units (RU) of surface plasmon resonance spectrum, wherein the human blood group B antigen comprises [Galα1-3(Fucα1-2)Gal-]; and

(c) selecting the candidate lactobacillus as a human blood group B-compatible lactobacillus if:

(i) blood group B antigen-recognizing ability is 2,000 RU or higher;

(ii) blood group A antigen-recognizing ability is 100 RU or lower;

(iii) blood group H antigen-recognizing ability is 100 RU or lower;

(iv) ratio of the blood group B antigen-recognizing ability to the blood group A antigen-recognizing ability is 50 or higher;

(v) ratio of the blood group B antigen-recognizing ability to the blood group H antigen-recognizing ability is 20 or higher; and

(vi) B-HCM-recognizing ability is higher than A-HCM-recognizing ability and O-HCM recognizing ability.

5. The method, according to claim 4 , wherein the human blood group A antigen comprises [GalNAcα1-3(Fucα1-2)Gal-].

6. The method, according to claim 4 , wherein the human blood group H antigen comprises [Fucα1-2Gal-].

7. A method of screening for a human blood group O-compatible lactobacillus , comprising:

(a) providing a candidate lactobacillus;

(b) determining ability of the candidate lactobacillus to recognize a human blood group A antigen, a human group B antigen, and a human group H antigen using surface plasmon resonance, wherein the recognizing ability is determined by measuring response units (RU) of surface plasmon resonance spectrum, wherein the human blood group H antigen comprises [Fucα1-2Gal-]; and

(c) selecting the candidate lactobacillus as a human blood group O-compatible lactobacillus if:

(i) blood group H antigen-recognizing ability is 700 RU or higher;

(ii) blood group A antigen-recognizing ability is 100 RU or lower;

(iii) blood group B antigen-recognizing ability is 100 RU or lower;

(iv) ratio of the blood group H anti en-recognizing ability to the blood group A antigen-recognizing ability is 800 or higher;

(v) ratio of the blood group H antigen-recognizing ability to the blood group B antigen-recognizing ability is 20 or higher;

(vi) O-HCM-recognizing ability is 100 RU or higher; and

(vii) A-HCM-recognizing ability is 1,000 RU or lower.

8. The method, according to claim 7 , wherein the human blood group A antigen comprises [GalNAcα1-3(Fucα1-2)Gal-].

9. The method, according to claim 7 , wherein the human blood group B antigen comprises [Galα1-3(Fucα1-2)Gal-].

Assignments (1)
CHANGE OF NAME Recorded Nov 17, 2011
From: MEIJI DAIRIES CORPORATION
To: MEIJI CO., LTD.
Reel/Frame 027244/0433 →
Priority Claims (2)
JP 2004-349135 · Dec 1, 2004 · national
WO PCT/JP2005/011043 · Jun 16, 2005 · international
Continuity (2)
Division 11720462
Related Publication 20110104721A1 · May 5, 2011